NP702156.RAktmfGf1R iCoDSMQiFqCUmkUQGfqZvJzegMUeBKfAzs
has assertion: NP702156.RAktmfGf1R iCoDSMQiFqCUmkUQGfqZvJzegMUeBKfAzs130 assertion
has provenance: NP702156.RAktmfGf1R iCoDSMQiFqCUmkUQGfqZvJzegMUeBKfAzs130 provenance
has publication info: NP702156.RAktmfGf1R iCoDSMQiFqCUmkUQGfqZvJzegMUeBKfAzs130 publicationInfo
type: Nanopublication
created: 2016-05-13T12:47:03+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP702156.RAktmfGf1R iCoDSMQiFqCUmkUQGfqZvJzegMUeBKfAzs130 assertion
type: Assertion
description: [Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/18990748
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0